Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Quartilho

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Eye (London, England)|August 1, 2015
Certification figures and their accuracyA Quartilho, A Zekite, W Xing, et al.
Eye (London, England)|January 30, 2016
Leading causes of certifiable visual loss in England and Wales during the year ending 31 March 2013A Quartilho, P Simkiss, A Zekite, et al.
Eye (London, England)|June 18, 2016
Uveitis certificationsA Quartilho, P Simkiss, A Zekite, et al.
Eye (London, England)|October 24, 2015
A randomized clinical trial comparing fixed vs pro-re-nata dosing of Ozurdex in refractory diabetic macular oedema (OZDRY study)J Ramu, Y Yang, G Menon, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Eye (London, England)|August 1, 2015
Certification figures and their accuracyA Quartilho, A Zekite, W Xing, et al.
Eye (London, England)|January 30, 2016
Leading causes of certifiable visual loss in England and Wales during the year ending 31 March 2013A Quartilho, P Simkiss, A Zekite, et al.
Eye (London, England)|June 18, 2016
Uveitis certificationsA Quartilho, P Simkiss, A Zekite, et al.
Eye (London, England)|October 24, 2015
A randomized clinical trial comparing fixed vs pro-re-nata dosing of Ozurdex in refractory diabetic macular oedema (OZDRY study)J Ramu, Y Yang, G Menon, et al.
Pageof 1